vs
Side-by-side financial comparison of CHOICE HOTELS INTERNATIONAL INC (CHH) and Orthofix Medical Inc. (OFIX). Click either name above to swap in a different company.
CHOICE HOTELS INTERNATIONAL INC is the larger business by last-quarter revenue ($340.6M vs $219.9M, roughly 1.5× Orthofix Medical Inc.). CHOICE HOTELS INTERNATIONAL INC runs the higher net margin — 5.9% vs -1.0%, a 6.9% gap on every dollar of revenue. On growth, CHOICE HOTELS INTERNATIONAL INC posted the faster year-over-year revenue change (2.3% vs 2.0%). Over the past eight quarters, Orthofix Medical Inc.'s revenue compounded faster (8.0% CAGR vs -11.5%).
Choice Hotels International, Inc. is an American multinational hospitality company based in North Bethesda, Maryland. The company, which is one of the largest hotel chains in the world, owns various hotel brands ranging from upscale to economy. As of the end of 2024, Choice Hotels franchised nearly 7,600 hotels, representing over 650,000 rooms, in 46 countries and territories.
Orthofix Medical Inc. is a global medical device firm specializing in orthopedic care. It develops, manufactures and sells spinal implants, trauma care products, bone growth stimulation therapies and regenerative medicine offerings, serving orthopedic surgeons and healthcare providers across North America, Europe and Asia Pacific.
CHH vs OFIX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $340.6M | $219.9M |
| Net Profit | $20.0M | $-2.2M |
| Gross Margin | — | 71.1% |
| Operating Margin | 17.6% | 0.2% |
| Net Margin | 5.9% | -1.0% |
| Revenue YoY | 2.3% | 2.0% |
| Net Profit YoY | -54.4% | 92.4% |
| EPS (diluted) | $0.44 | $-0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $340.6M | — | ||
| Q4 25 | $390.1M | $219.9M | ||
| Q3 25 | $447.3M | $205.6M | ||
| Q2 25 | $426.4M | $203.1M | ||
| Q1 25 | $332.9M | $193.6M | ||
| Q4 24 | $389.8M | $215.7M | ||
| Q3 24 | $428.0M | $196.6M | ||
| Q2 24 | $435.2M | $198.6M |
| Q1 26 | $20.0M | — | ||
| Q4 25 | $63.7M | $-2.2M | ||
| Q3 25 | $180.0M | $-22.8M | ||
| Q2 25 | $81.7M | $-14.1M | ||
| Q1 25 | $44.5M | $-53.1M | ||
| Q4 24 | $75.8M | $-29.1M | ||
| Q3 24 | $105.7M | $-27.4M | ||
| Q2 24 | $87.1M | $-33.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% |
| Q1 26 | 17.6% | — | ||
| Q4 25 | 26.0% | 0.2% | ||
| Q3 25 | 31.8% | -8.3% | ||
| Q2 25 | 29.2% | -7.9% | ||
| Q1 25 | 24.0% | -25.2% | ||
| Q4 24 | 30.6% | -5.3% | ||
| Q3 24 | 35.5% | -9.6% | ||
| Q2 24 | 30.5% | -12.5% |
| Q1 26 | 5.9% | — | ||
| Q4 25 | 16.3% | -1.0% | ||
| Q3 25 | 40.2% | -11.1% | ||
| Q2 25 | 19.2% | -6.9% | ||
| Q1 25 | 13.4% | -27.4% | ||
| Q4 24 | 19.4% | -13.5% | ||
| Q3 24 | 24.7% | -13.9% | ||
| Q2 24 | 20.0% | -16.8% |
| Q1 26 | $0.44 | — | ||
| Q4 25 | $1.35 | $-0.05 | ||
| Q3 25 | $3.86 | $-0.57 | ||
| Q2 25 | $1.75 | $-0.36 | ||
| Q1 25 | $0.94 | $-1.35 | ||
| Q4 24 | $1.56 | $-0.76 | ||
| Q3 24 | $2.22 | $-0.71 | ||
| Q2 24 | $1.80 | $-0.88 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $43.9M | $82.0M |
| Total DebtLower is stronger | $2.0B | — |
| Stockholders' EquityBook value | $137.4M | $450.0M |
| Total Assets | $2.9B | $850.6M |
| Debt / EquityLower = less leverage | 14.58× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $43.9M | — | ||
| Q4 25 | $45.0M | $82.0M | ||
| Q3 25 | $52.6M | $62.9M | ||
| Q2 25 | $58.6M | $65.6M | ||
| Q1 25 | $40.1M | $58.0M | ||
| Q4 24 | $40.2M | $83.2M | ||
| Q3 24 | $58.6M | $30.1M | ||
| Q2 24 | $60.4M | $26.4M |
| Q1 26 | $2.0B | — | ||
| Q4 25 | $1.9B | — | ||
| Q3 25 | $1.9B | $157.2M | ||
| Q2 25 | $1.9B | $157.0M | ||
| Q1 25 | $1.9B | $156.9M | ||
| Q4 24 | $1.8B | $157.0M | ||
| Q3 24 | $1.8B | $118.5M | ||
| Q2 24 | $1.9B | $118.0M |
| Q1 26 | $137.4M | — | ||
| Q4 25 | $181.2M | $450.0M | ||
| Q3 25 | $149.8M | $442.5M | ||
| Q2 25 | $-26.2M | $458.3M | ||
| Q1 25 | $-63.9M | $458.3M | ||
| Q4 24 | $-45.3M | $503.1M | ||
| Q3 24 | $-96.2M | $525.9M | ||
| Q2 24 | $-146.8M | $546.0M |
| Q1 26 | $2.9B | — | ||
| Q4 25 | $2.9B | $850.6M | ||
| Q3 25 | $2.9B | $832.6M | ||
| Q2 25 | $2.7B | $837.2M | ||
| Q1 25 | $2.6B | $823.1M | ||
| Q4 24 | $2.5B | $893.3M | ||
| Q3 24 | $2.5B | $867.9M | ||
| Q2 24 | $2.5B | $882.0M |
| Q1 26 | 14.58× | — | ||
| Q4 25 | 10.52× | — | ||
| Q3 25 | 12.81× | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $27.7M |
| Free Cash FlowOCF − Capex | — | $16.8M |
| FCF MarginFCF / Revenue | — | 7.6% |
| Capex IntensityCapex / Revenue | — | 4.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-1.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $85.7M | $27.7M | ||
| Q3 25 | $68.7M | $12.4M | ||
| Q2 25 | $95.6M | $11.6M | ||
| Q1 25 | $20.5M | $-18.4M | ||
| Q4 24 | $82.9M | $23.7M | ||
| Q3 24 | $122.9M | $11.7M | ||
| Q2 24 | $111.9M | $9.0M |
| Q1 26 | — | — | ||
| Q4 25 | $64.1M | $16.8M | ||
| Q3 25 | $49.1M | $2.5M | ||
| Q2 25 | $65.4M | $4.5M | ||
| Q1 25 | $-15.0M | $-25.1M | ||
| Q4 24 | $57.4M | $15.2M | ||
| Q3 24 | $92.6M | $6.3M | ||
| Q2 24 | $86.6M | $-360.0K |
| Q1 26 | — | — | ||
| Q4 25 | 16.4% | 7.6% | ||
| Q3 25 | 11.0% | 1.2% | ||
| Q2 25 | 15.3% | 2.2% | ||
| Q1 25 | -4.5% | -13.0% | ||
| Q4 24 | 14.7% | 7.0% | ||
| Q3 24 | 21.6% | 3.2% | ||
| Q2 24 | 19.9% | -0.2% |
| Q1 26 | — | — | ||
| Q4 25 | 5.5% | 4.9% | ||
| Q3 25 | 4.4% | 4.8% | ||
| Q2 25 | 7.1% | 3.5% | ||
| Q1 25 | 10.7% | 3.5% | ||
| Q4 24 | 6.5% | 4.0% | ||
| Q3 24 | 7.1% | 2.7% | ||
| Q2 24 | 5.8% | 4.7% |
| Q1 26 | — | — | ||
| Q4 25 | 1.35× | — | ||
| Q3 25 | 0.38× | — | ||
| Q2 25 | 1.17× | — | ||
| Q1 25 | 0.46× | — | ||
| Q4 24 | 1.09× | — | ||
| Q3 24 | 1.16× | — | ||
| Q2 24 | 1.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CHH
| Franchise and management fees | $149.6M | 44% |
| Other | $135.8M | 40% |
| Owned hotels | $30.4M | 9% |
| Partnership services and fees | $24.7M | 7% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
